Chinless wonder as aesthetic specialist Kythera rises after floating at high end
This article was originally published in Scrip
Executive Summary
Aesthetically-focused Kythera Biopharmaceuticals didn't rely on beauty alone to boost its $70.4 million initial public offering on 11 October - the late-stage status of the company's chin-thinning product and previously reported positive Phase III clinical trial results likely appealed to stock buyers who have been wary of earlier-stage investments.